Delivering what's next in genetic medicine.
Averna Therapeutics (formerly Exsilio Therapeutics) is a biotechnology company developing RNA/lipid nanoparticle (LNP)-based genomic medicines designed to durably insert any gene or genetic instruction of interest into cells. The company's platform leverages site-specific retrotransposons — nature's precision gene insertion system — to safely integrate large sets of genetic instructions at safe harbor genomic locations without disrupting cell function. Averna's all-RNA system, delivered by LNPs, aims to expand the reach of genetic medicines beyond what viral approaches can achieve, broadening addressable diseases and patient populations. The company was recognized as a 2025 Endpoints 11 Most Promising Biotech.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJun 2024
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
BridgeBio makes targeted treatments for genetic diseases.
